MedAdvisor Limited (AU:MDR) has released an update.
MedAdvisor Limited is on track to achieve record financial results for FY24 with strong growth momentum in the U.S. and Australia, leading to its first full-year EBITDA and NPAT profit, with revenues expected to increase by $22-25 million. The company’s success is driven by its THRiV programs in the U.S. and new transaction fees in Australia, with a positive outlook for continued growth into FY25.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.
